Glaucoma Therapeutics Market

Glaucoma Therapeutics Market Report By Drug Class (Prostaglandins, Beta Blockers, Alpha Agonists, Carbonic, Anhydrase Inhibitors, Combination Medications, Cholinergic Medications), By End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers) - Regional Forecast 2021-2031

Analysis of Glaucoma Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Request FREE Sample

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glaucoma Therapeutics Market 

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2021–2031

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Value Chain Analysis

    5.2. Disease Prevalence & Incidence Rate, by Region

    5.3. Healthcare Industry Overview

    5.4. Pipeline Analysis

6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2021–2031

        6.3.1. Prostaglandins

        6.3.2. Beta Blockers

        6.3.3. Alpha Agonists

        6.3.4. Carbonic Anhydrase Inhibitors

        6.3.5. Combination Medications

        6.3.6. Cholinergics

    6.4. Market Attractiveness, by Drug Class 

7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2021–2031

        7.3.1. Hospitals

        7.3.2. Ophthalmic Clinics

        7.3.3. Ambulatory Surgical Centers

    7.4. Market Attractiveness, by End-user 

8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness, by Country/Region

9. North America Glaucoma Therapeutics Market Analysis and Forecast

    9.1. Introduction

    9.2. Market Value Forecast, by Drug Class, 2021–2031

        9.2.1. Prostaglandins

        9.2.2. Beta Blockers

        9.2.3. Alpha Agonists

        9.2.4. Carbonic Anhydrase Inhibitors

        9.2.5. Combination Medications

        9.2.6. Cholinergics

    9.3. Market Value Forecast, by End-user, 2021–2031

        9.3.1. Hospitals

        9.3.2. Ophthalmic Clinics

        9.3.3. Ambulatory Surgical Centers

    9.4. Market Value Forecast, by Country, 2021–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis 

        9.5.1. By Drug Class 

        9.5.2. By End-user 

        9.5.3. By Country

10. Europe Glaucoma Therapeutics Market Analysis and Forecast

    10.1. Introduction

    10.2. Market Value Forecast, by Drug Class, 2021–2031

        10.2.1. Prostaglandins

        10.2.2. Beta Blockers

        10.2.3. Alpha Agonists

        10.2.4. Carbonic Anhydrase Inhibitors

        10.2.5. Combination Medications

        10.2.6. Cholinergics

    10.3. Market Value Forecast, by End-user, 2021–2031

        10.3.1. Hospitals

        10.3.2. Ophthalmic Clinics

        10.3.3. Ambulatory Surgical Centers

    10.4. Market Value Forecast, by Country/Sub-region, 2021–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis 

        10.5.1. By Drug Class 

        10.5.2. By End-user 

        10.5.3. By Country/Sub-region

11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast

    11.1. Introduction

    11.2. Market Value Forecast, by Drug Class, 2021–2031

        11.2.1. Prostaglandins

        11.2.2. Beta Blockers

        11.2.3. Alpha Agonists

        11.2.4. Carbonic Anhydrase Inhibitors

        11.2.5. Combination Medications

        11.2.6. Cholinergics

    11.3. Market Value Forecast, by End-user, 2021–2031

        11.3.1. Hospitals

        11.3.2. Ophthalmic Clinics

        11.3.3. Ambulatory Surgical Centers

    11.4. Market Value Forecast, by Country/Sub-region, 2021–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis 

        11.5.1. By Drug Class 

        11.5.2. By End-user 

        11.5.3. By Country/Sub-region

12. Latin America Glaucoma Therapeutics Market Analysis and Forecast

    12.1. Introduction

    12.2. Market Value Forecast, by Drug Class, 2021–2031

        12.2.1. Prostaglandins

        12.2.2. Beta Blockers

        12.2.3. Alpha Agonists

        12.2.4. Carbonic Anhydrase Inhibitors

        12.2.5. Combination Medications

        12.2.6. Cholinergics

    12.3. Market Value Forecast, by End-user, 2021–2031

        12.3.1. Hospitals

        12.3.2. Ophthalmic Clinics

        12.3.3. Ambulatory Surgical Centers

    12.4. Market Value Forecast, by Country/Sub-region, 2021–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis 

        12.5.1. By Drug Class 

        12.5.2. By End-user 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast

    13.1. Introduction

    13.2. Market Value Forecast, by Drug Class, 2021–2031

        13.2.1. Prostaglandins

        13.2.2. Beta Blockers

        13.2.3. Alpha Agonists

        13.2.4. Carbonic Anhydrase Inhibitors

        13.2.5. Combination Medications

        13.2.6. Cholinergics

    13.3. Market Value Forecast, by End-user, 2021–2031

        13.3.1. Hospitals

        13.3.2. Ophthalmic Clinics

        13.3.3. Ambulatory Surgical Centers

    13.4. Market Value Forecast, by Country/Sub-region, 2021–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis 

        13.5.1. By Drug Class 

        13.5.2. By End-user 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix 

    14.2. Market Share Analysis, by Company (2020)

    14.3. Company Profiles

        14.3.1. Allergan plc

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Financial Overview

            14.3.1.3. Product Portfolio

            14.3.1.4. SWOT Analysis

            14.3.1.5. Strategic Overview

        14.3.2. Merck & Co., Inc.

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Financial Overview

            14.3.2.3. Product Portfolio

            14.3.2.4. SWOT Analysis

            14.3.2.5. Strategic Overview

        14.3.3. Novartis AG

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Financial Overview

            14.3.3.3. Product Portfolio

            14.3.3.4. SWOT Analysis

            14.3.3.5. Strategic Overview

        14.3.4. Pfizer Inc. 

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Financial Overview

            14.3.4.3. Product Portfolio

            14.3.4.4. SWOT Analysis

            14.3.4.5. Strategic Overview

        14.3.5. Santen Pharmaceuticals Co. Ltd.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Financial Overview

            14.3.5.3. Product Portfolio

            14.3.5.4. SWOT Analysis

            14.3.5.5. Strategic Overview

        14.3.6. Valeant Pharmaceuticals International, Inc.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Financial Overview

            14.3.6.3. Product Portfolio

            14.3.6.4. SWOT Analysis

            14.3.6.5. Strategic Overview

        14.3.7. Aerie Pharmaceuticals Inc.

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. SWOT Analysis

            14.3.7.4. Strategic Overview

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 02: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2021–2031

Table 03: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2021–2031

Table 04: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 05: North America Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 06: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2021–2031

Table 07: U.S. Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 08: U.S. Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 09: Canada Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 10: Canada Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 11: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 12: Europe Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 13: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 14: U.K. Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 15: U.K. Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 16: Germany Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 17: Germany Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 18: France Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 19: France Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 20: Spain Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 21: Spain Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 22: Italy Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 23: Italy Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 24: Rest of Europe Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 25: Rest of Europe Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 26: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 27: Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 28: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 29: Japan Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 30: Japan Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 31: China Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 32: China Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 33: India Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 34: India Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 35: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 36: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 37: Rest of APAC Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 38: Rest of APAC Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 39: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 40: Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 41: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 42: Brazil Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 43: Brazil Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 44: Mexico Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 45: Mexico Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 46: Rest of LATAM Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 47: Rest of LATAM Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 48: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 49: Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 50: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2021–2031

Table 51: GCC Countries Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 52: GCC Countries Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 53: South Africa Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 54: South Africa Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

Table 55: Rest of MEA Glaucoma Therapeutics Market Forecast, by Drug Class, 2021–2031

Table 56: Rest of MEA Glaucoma Therapeutics Market Forecast, by End-user, 2021–2031

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Glaucoma Therapeutics Market Snapshot

Figure 02: Global Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2021–2031

Figure 03: Market Value Share, by Drug Class (2020)

Figure 04: Market Value Share, by End-user (2020)

Figure 05: Market Value Share, by Region (2020)

Figure 06: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 07: Global Prostaglandins Market Revenue (US$ Mn), 2021–2031

Figure 08: Global Beta Blockers Market Revenue (US$ Mn), 2021–2031

Figure 09: Global Alpha Agonist Market, Revenue (US$ Mn), 2021–2031

Figure 10: Global Carbonic Anhydrase Inhibitor (CAI) Market, Revenue (US$ Mn), 2021–2031

Figure 11: Global Combination Medications Market, Revenue (US$ Mn), 2021–2031

Figure 12: Global Cholinergic Market, Revenue (US$ Mn), 2021–2031

Figure 13: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class

Figure 14: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 15: Global Hospitals Market Revenue (US$ Mn), 2021–2031

Figure 16: Global Ophthalmic Clinics Market Revenue (US$ Mn), 2021–2031

Figure 17: Global Ambulatory Surgical Centers Market Revenue (US$ Mn), 2021–2031

Figure 18: Global Glaucoma Therapeutics Market Attractiveness Analysis, by End-user

Figure 19: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2021 and 2031

Figure 20: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2020–2031

Figure 21: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2021–2031

Figure 22: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country

Figure 23: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 24: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 25: North America Glaucoma Therapeutics Market, by Country, 2021 and 2031

Figure 26: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class

Figure 27: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user

Figure 28: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2021–2031

Figure 29: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region

Figure 30: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 31: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 32: Europe Glaucoma Therapeutics Market, by Country/Sub-region

Figure 33: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class

Figure 34: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user

Figure 35: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2021–2031

Figure 36: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region

Figure 37: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 38: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 39: Asia Pacific Glaucoma Therapeutics Market, by Country/Sub-region

Figure 40: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class

Figure 41: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user

Figure 42: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2021–2031

Figure 43: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region

Figure 44: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 45: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 46: North America Glaucoma Therapeutics Market, by Country/Sub-region

Figure 47: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class

Figure 48: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user

Figure 49: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2021–2031

Figure 50: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region

Figure 51: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 52: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

Figure 53: Middle East & Africa Glaucoma Therapeutics Market, by Country/Sub-region

Figure 54: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class

Figure 55: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user

Figure 56: Global Glaucoma Therapeutics Market Share Analysis, by Company (2020)

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Glaucoma Therapeutics Market

Schedule a Call

Copyright © Fact.MR All Rights Reserved

An initiative of Eminent Research and Advisory Services